Clinical trial · Observational
CD147 Targeting Peptide Probe for PET Imaging in Solid Tumors
NCT06720298CI-TRIAL-00084081not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of the study is to construct a noninvasive approach using 68Ga-DOTA-AP9 PET/CT to detect the CD147 expression of tumor lesions in patients with solid tumors and to identify patients benefiting from CD147 targeting treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18F-FDG | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- 68Ga-DOTA-AP9
- description
- All enrolled participants will be allocated to this arm (single-arm study). Study participants will undergo 68Ga-DOTA-AP9 PET/CT scan.
- interventionNames
- Drug: 18F-FDG
Primary outcomes (1)
- measure
- Standardized uptake value（SUV）
- timeFrame
- 2 years
- description
- SUV is a semi-quantitative analysis index to describe the radioactive uptake of lesions, which has certain reference value for differentiating benign and malignant lesions. The uptake of the tracer （68Ga-DOTA-AP9） in solid tumor lesions by measuring SUV on PET/CT.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Malignant melanoma, liver cancer, colon cancer, pancreatic cancer, breast cancer, gastric cancer, lung cancer, etc., confirmed by histopathology or cytology; 2. age ≥18 and ≤75 years old, male or female; 3. ECOG score 0 or 1; 4. expected survival time ≥6 months; 5. There was at least one measurable target lesion according to RECIST1.1 criteria, and biopsy could be performed within one month before and after PET scan, and the patient could provide 2-3 lesion tissue slides; 6. Women of childbearing age (15-49 years) must have had a negative pregnancy test within 7 days before starting testing; Women and men of childbearing potential must agree to use effective contraception to avoid pregnancy during the study and for 3 months after the examination; 7. patients recommended by clinicians to undergo PET/CT examination for tumor staging; 8. The subjects could fully understand and voluntarily participate in this experiment, and signed an informed consent. Exclusion Criteria: 1. Pregnant or breastfeeding women, or women planning to become pregnant during the study or within three months after administration, as well as individuals donating sperm or oocytes. 2. Individuals known or suspected to be allergic to the investigational drug or any of its components. 3. Individuals with significantly abnormal liver or kidney function: serum total bilirubin (TBIL) \> 1.5 × 20 µmol/L, or aspartate aminotransferase (AST) \> 2.5 × 45 µmol/L, or alanine aminotransferase (ALT) \> 2.5 × 40 µmol/L, or serum creatinine \> 1.5 × 130 µmol/L. 4. Unable to cooperate in completing the PET scan, or suffering from claustrophobia or other conditions that prevent cooperation during the PET scan. 5. Other situations deemed inappropriate for participation in the trial by the investigator. Female patients who are pregnant or breastfeeding.
References
Publications (0)
Data not yet available
No reference posted for this study.